Blueprint Medicines (BPMC)
(Delayed Data from NSDQ)
$105.55 USD
-0.84 (-0.79%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $105.45 -0.10 (-0.09%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Industry / Sector Report
Industry : Medical - Biomedical and Genetics
Zacks Industry Rank
Top 36% (89 out of 250)Zacks Sector Rank
Top 44% (7 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 1.76 | 1.35 | 9.99 |
Current Quarter Estimate | -1.30 | 7.43 | 57.00 |
Year Ago Quarter Estimate | -2.19 | 0.12 | 52.54 |
Next Quarter Estimate | -1.14 | 7.81 | 61.00 |
Next Year Estimate | -2.25 | 37.76 | 270.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | 70.73 | 15.60 | 15.67 |
Next Year | 8.16 | 9.00 | 9.31 |
Last 5 Years | -339.50 | 3.70 | 8.10 |
Next 5 Years | 34.00 | 20.70 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | NA | -2.18 |
Price/Book (MRQ) | 20.79 | 2.10 |
Price/Cash Flow (MRFY) | NA | 17.94 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | -102.15% | -167.94% |
Return on Equity (TTM) | -193.48% | -59.47% |
Debt to Equity (MRQ) | 0.67 | 0.00 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.